Roivant Sciences

ROIVNasdaq United Kingdom Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$26.262 B

$36.34 +3.47%

Close of 7 Aug 2026

Revenue

$8.26M

#3208 by revenue

Earnings

-$299.8M

Loss-making

Shares outstanding

722,323,015

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations — ranked by market cap

All 501 →

#20Alnylam PharmaceuticalsALNY$29.3B
#21InsmedINSM$28.4B
#22Roivant SciencesROIV$26.3B
#23United TherapeuticsUTHR$23.1B
#24ViatrisVTRS$19.1B

Where these numbers come from

Share counts and financials for Roivant Sciences are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.